QQQ   444.71 (-0.03%)
AAPL   171.07 (-1.29%)
MSFT   420.54 (-0.21%)
META   487.04 (-1.38%)
GOOGL   150.44 (-0.29%)
AMZN   180.34 (+0.28%)
TSLA   176.60 (-1.80%)
NVDA   907.00 (+0.50%)
NIO   4.63 (-0.86%)
AMD   182.06 (+1.38%)
BABA   72.48 (+1.24%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.21 (-0.78%)
CGC   9.81 (+2.72%)
GE   175.20 (-2.73%)
DIS   122.87 (+1.56%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   67.13 (+0.84%)
XOM   115.63 (+0.57%)
QQQ   444.71 (-0.03%)
AAPL   171.07 (-1.29%)
MSFT   420.54 (-0.21%)
META   487.04 (-1.38%)
GOOGL   150.44 (-0.29%)
AMZN   180.34 (+0.28%)
TSLA   176.60 (-1.80%)
NVDA   907.00 (+0.50%)
NIO   4.63 (-0.86%)
AMD   182.06 (+1.38%)
BABA   72.48 (+1.24%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.21 (-0.78%)
CGC   9.81 (+2.72%)
GE   175.20 (-2.73%)
DIS   122.87 (+1.56%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   67.13 (+0.84%)
XOM   115.63 (+0.57%)
QQQ   444.71 (-0.03%)
AAPL   171.07 (-1.29%)
MSFT   420.54 (-0.21%)
META   487.04 (-1.38%)
GOOGL   150.44 (-0.29%)
AMZN   180.34 (+0.28%)
TSLA   176.60 (-1.80%)
NVDA   907.00 (+0.50%)
NIO   4.63 (-0.86%)
AMD   182.06 (+1.38%)
BABA   72.48 (+1.24%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.21 (-0.78%)
CGC   9.81 (+2.72%)
GE   175.20 (-2.73%)
DIS   122.87 (+1.56%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   67.13 (+0.84%)
XOM   115.63 (+0.57%)
QQQ   444.71 (-0.03%)
AAPL   171.07 (-1.29%)
MSFT   420.54 (-0.21%)
META   487.04 (-1.38%)
GOOGL   150.44 (-0.29%)
AMZN   180.34 (+0.28%)
TSLA   176.60 (-1.80%)
NVDA   907.00 (+0.50%)
NIO   4.63 (-0.86%)
AMD   182.06 (+1.38%)
BABA   72.48 (+1.24%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.21 (-0.78%)
CGC   9.81 (+2.72%)
GE   175.20 (-2.73%)
DIS   122.87 (+1.56%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   67.13 (+0.84%)
XOM   115.63 (+0.57%)
OTCMKTS:TRUMY

Terumo (TRUMY) Stock Price, News & Analysis

$37.36
+0.45 (+1.22%)
(As of 03/27/2024 ET)
Today's Range
$36.73
$38.09
50-Day Range
$33.43
$39.67
52-Week Range
$25.11
$41.19
Volume
29,362 shs
Average Volume
13,792 shs
Market Capitalization
$27.93 billion
P/E Ratio
39.32
Dividend Yield
0.59%
Price Target
N/A
TRUMY stock logo

About Terumo Stock (OTCMKTS:TRUMY)

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritious food products, adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Tokyo, Japan.

TRUMY Stock Price History

TRUMY Stock News Headlines

Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Improved Revenue Growth Is Terumo's Next Major Target
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Lakewood Company Putting People at Risk?
Ivanka Trump
Trump Reinstated To Facebook And Instagram
OMG. Trump Has Started Texting.
See More Headlines
Receive TRUMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Terumo and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/07/2024
Today
3/28/2024
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical & hospital equipment
Sub-Industry
N/A
Current Symbol
OTCMKTS:TRUMY
Previous Symbol
NASDAQ:TRUMY
Employees
30,207
Year Founded
1964

Profitability

Net Income
$661.01 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$6.07 billion
Cash Flow
$1.62 per share
Book Value
$11.00 per share

Miscellaneous

Free Float
N/A
Market Cap
$27.93 billion
Optionable
Not Optionable
Beta
0.65

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Shinjiro Sato (Age 64)
    President, CEO, Group Managing Executive Officer & Director
    Comp: $825.21k
  • Mr. Naoki Muto
    Chief Accounting & Financial Officer and Group Executive Officer
  • Itaru Sakaguchi
    Senior Executive Officer & COO
  • Fumihisa Hirose
    Group Managing Executive Officer, GM of Strategic Planning Department & CTO
  • Mr. Shoji Hatano (Age 65)
    Group Senior Mng. Exe. Off. of Corporate Affairs Dept., Legal and Compliance Dept. & Director
  • Ms. Miho Mizuguchi
    Executive Officer, Chief Legal Officer and GM of CLO Office, Legal & Compliance Department
  • Tomoko Adachi
    Chief Human Resources Officer & Group Executive Officer
  • James Rushworth
    Group Executive Officer & Chief Commercial Officer
  • Mr. Hikaru Samejima (Age 60)
    Group Senior Managing Executive & Director
  • Mr. Kazunori Hirose (Age 60)
    Group Managing Executive Officer, Chief Manufacturing Officer & Director

Should I Buy Terumo Stock? TRUMY Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Terumo was last updated on Wednesday, March 27, 2024 at 11:26 PM.

Pros

Here are some ways that investors could benefit from investing in Terumo Co.:

  • Terumo India launched a new drug-eluting stent, Ultimaster Nagomi, showcasing the company's commitment to innovation and product development in the medical devices sector.
  • Terumo Corporation operates in multiple segments including Cardiac and Vascular, Medical Care Solutions, and Blood and Cell Technologies, providing diversification and exposure to various areas of the healthcare industry.
  • The company has a long history dating back to 1921, demonstrating stability and experience in the medical and hospital equipment industry.
  • Terumo's global presence in Japan, Europe, China, the United States, and Asia offers geographic diversification and access to different markets.
  • Recent developments such as the launch of new products and technologies indicate a focus on staying competitive and meeting evolving healthcare needs.

Cons

Investors should be bearish about investing in Terumo Co. for these reasons:

  • Market volatility and regulatory challenges in the medical equipment industry can impact the company's performance and stock price.
  • Competition from other medical device companies may pose a threat to Terumo's market share and profitability.
  • Global economic conditions and healthcare spending trends can influence demand for Terumo's products and services.
  • Fluctuations in currency exchange rates could affect the company's international operations and financial results.
  • Investors should carefully monitor the company's financial performance, product pipeline, and competitive positioning to make informed investment decisions.

TRUMY Stock Analysis - Frequently Asked Questions

Should I buy or sell Terumo stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Terumo in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TRUMY shares.
View TRUMY analyst ratings
or view top-rated stocks.

How have TRUMY shares performed in 2024?

Terumo's stock was trading at $32.62 at the beginning of the year. Since then, TRUMY stock has increased by 14.5% and is now trading at $37.3550.
View the best growth stocks for 2024 here
.

Are investors shorting Terumo?

Terumo saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 700 shares, a decline of 76.7% from the February 29th total of 3,000 shares. Based on an average daily trading volume, of 27,800 shares, the short-interest ratio is currently 0.0 days.
View Terumo's Short Interest
.

How were Terumo's earnings last quarter?

Terumo Co. (OTCMKTS:TRUMY) posted its earnings results on Wednesday, February, 7th. The company reported $0.27 EPS for the quarter, hitting the consensus estimate of $0.27. The company had revenue of $1.62 billion for the quarter. Terumo had a net margin of 11.14% and a trailing twelve-month return on equity of 8.26%.

Is Terumo a good dividend stock?

Terumo (OTCMKTS:TRUMY) pays an annual dividend of $0.22 per share and currently has a dividend yield of 0.59%. The dividend payout ratio is 23.16%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TRUMY will have a dividend payout ratio of 16.54% next year. This indicates that the company will be able to sustain or increase its dividend.

When did Terumo's stock split?

Terumo's stock split on Thursday, March 28th 2024. The 2-1 split was announced on Thursday, March 28th 2024. The newly issued shares will be distributed to shareholders after the market closes on Thursday, March 28th 2024. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

How do I buy shares of Terumo?

Shares of TRUMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:TRUMY) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners